MegaPro Biomedical Co. Ltd.
A clinical-stage biotech developing nanomedicines for oncology and diagnostics.
TPEX
Overview
Corporate Details
- ISIN(s):
- TW0006827009
- LEI:
- Country:
- Malaysia
- Address:
- N/A
- Website:
- https://www.megaprobio.com/en/
Description
MegaPro Biomedical Co., Ltd. is a clinical-stage biotechnology company specializing in the development of nano drugs and advanced nanomedicine platforms. The company utilizes its proprietary nano-cell technology, centered on nano iron oxide particles, to create novel therapeutics and diagnostic agents. Its diversified pipeline targets oncology, diagnostic imaging, and hematology. Key programs in clinical development include MPB-1734, a new formulation anti-cancer drug; MPB-2043, a magnetic resonance imaging (MRI) contrast agent for cancer staging; and MPB-1514, an iron injection for the treatment of iron deficiency anemia. The company actively advances its portfolio through integrated research and development and the execution of clinical trials for its nanomedicine candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-30 04:05 |
MegaPro s MPB-1734 Expected to Seek Prostate Cancer NDA via 505(b)(2) Pathway S…
|
English | 7.1 KB |
Automate Your Workflow. Get a real-time feed of all MegaPro Biomedical Co. Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MegaPro Biomedical Co. Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MegaPro Biomedical Co. Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
